Amgen (AMGN) call put ratio 1 to 1 into Q2 and outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Amgen (AMGN) PT Raised to $195 at Barclays
July 27, 2018 6:56 AM EDTBarclays raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Equalweight rating following the company's 2Q earnings report.
Amgens portfolio looks poised to deliver flat growth in 2018e, which, in Barclays view, will likely keep... More
Amgen (AMGN) PT Raised to $210 at Piper Jaffray Following 2Q
July 27, 2018 6:45 AM EDTPiper Jaffray raised its price target on Amgen (NASDAQ: AMGN) to $210.00 (from $190.00) while maintaining a Overweight rating following the company's 2Q earnings report. AMGN posted Q218 non-GAAP EPS of $3.83, well ahead of consensus $3.55. Upside was operationally driven as revenue beat handily (total revenue was... More
